drugset / Trial / NCT02628392

A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT02628392

Completed 368 enrolled Daiichi Sankyo
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of the study is to evaluate the efficacy, safety, and dose of DS-8500a compared with placebo in patients with type 2 diabetes mellitus.

Timeline

Start
2015-11
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject FIRUGLIPEL Small molecule 25 mg Oral
Subject FIRUGLIPEL Small molecule 50 mg Oral
Subject FIRUGLIPEL Small molecule 75 mg Oral
Comparator Sitagliptin Small molecule Oral